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Abstract:  Etravirine  is  an  oral  diarylpyrimidine  compound,  a  second-generation  human 
immunodeficiency virus type 1 (HIV-1) non-nucleoside reverse transcriptase inhibitor (NNRTI) 
with expanded antiviral activity against NNRTI-resistant HIV-1, to be used in combination 
therapy for treatment-experienced patients. Compared with first-generation NNRTIs, etravirine 
has a high genetic barrier to resistance, and is better tolerated without the neuropsychiatric and 
hepatic side effects of efavirenz and nevirapine, respectively. Its safety profile is comparable to 
placebo with the exception of rash, which has been mild and self-limited in the great majority 
of patients. In phase III clinical trials among treatment-experienced patients harboring NNRTI-
resistant HIV-1, etravirine in combination with an optimized background regimen (OBR) 
that included ritonavir-boosted darunavir demonstrated superior antiviral activity than the 
control OBR. In addition, patients on the etravirine arm had fewer AIDS-defining conditions, 
hospitalizations, and lower mortality compared with the OBR control arm.
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Introduction
Over the last 14 years, combination antiretroviral therapy has led to adequate sup-
pression of human immunodeficiency virus (HIV) replication, immunologic recovery, 
and a dramatic decline in morbidity and mortality among HIV-infected individuals in 
the industrialized world, and to a lesser degree in developing countries.1–5 The goal 
of antiretroviral therapy is to suppress HIV replication to undetectable levels. The 
International AIDS Society-USA Panel currently recommends the combination of 
2 reverse transcriptase inhibitors and either the non-nucleoside reverse transcriptase 
inhibitor (NNRTI) or the ritonavir-boosted protease inhibitor (PI) as the initial therapy.6 
However, virologic suppression is not always achieved or maintained due to a variety 
of reasons, such as poor tolerability due to side effects leading to poor compliance, 
drug-to-drug interactions, and HIV drug resistance. Over the last few years, the use of 
an NNRTI, such as efavirenz in industrialized countries and nevirapine in resource-
limited settings, had been preferred for first-line treatment due to its high potency 
and low pill burden.6 However, efavirenz and nevirapine have a low genetic barrier 
to resistance, so that a single amino acid substitution in the viral reverse transcriptase 
(RT), such as K103N, leads to profound reduction in viral susceptibility to both drugs, 
conferring class-wide drug resistance.7 Transmitted NNRTI drug resistance has been 
increasing in adolescents and young adults in industrialized countries.8–10 Additionally, 
transmitted NNRTI drug resistance, in particular the mutation in position K103N, has 
been shown to persist several years in the absence of drug pressure.11 In developing HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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countries where single-dose nevirapine is being used to 
prevent mother-to-child HIV transmission, the prevalence 
of nevirapine drug resistance has been as high as 35% and 
52% among women and infants exposed to single-dose 
nevirapine, respectively.12
Etravirine (Intelence®; Tibotec Therapeutics, Raritan, 
New Jersey), formerly known as TMC125, is a second-
generation NNRTI that was approved by the US Food and 
Drug Administration (FDA) in January 2008 for use in 
HIV-1-infected individuals at a dose of 200 mg (two 100-mg 
tablets) twice a day. Its indication is for treatment-experi-
enced adults with evidence of NNRTI drug resistance.13 
Etravirine is a diarylpyrimidine compound that emerged 
after a long parallel screening process, involving testing 
candidate compounds from a series of diarylpyrimidines 
against wild-type and selected single- and double-mutant, 
NNRTI-resistant HIV-1 isolates.14 Etravirine is highly active 
against wild-type HIV-1 with a 50% effective concentra-
tion (EC50) of 1.4–4.8 nM and shows some activity against 
HIV-2 with an EC50 of 3.5 µM. In addition, etravirine 
retained activity with an EC50 , 100 nM against 97% of 
1,081 clinically derived recombinant viruses resistant to at 
least one of the first-generation NNRTIs.14,15 Etravirine has 
a diarylpyrimidine-based structure with molecular flexibility 
that allows it to accommodate to mutational changes in the 
RT binding pocket.16 The NNRTI binding sites are located 
in codons 100 to 110 and 180 to 190. The presence of the 
K103N and Y181C mutations reduces the NNRTI bind-
ing affinity, leading to drug resistance.17 Etravirine has a 
higher genetic barrier to HIV drug resistance, with activity 
against efavirenz- and nevirapine-resistant HIV-1 isolates 
harboring the K103N and Y181C mutations.14 Etravirine, 
as other NNRTI, is a noncompetitive inhibitor of the HIV 
RT enzyme; by binding to the hydrophobic pocket proximal 
to the active site, it causes a conformational change in the 
enzyme and disrupts its function.16 Etravirine has an ability 
to bind to the RT enzyme even in the presence of such muta-
tions. Its structure allows etravirine to bind to the enzyme in 
several modes due to the conformational adaptation based 
on changes in the binding pocket.16 The torsional flexibility 
allows etravirine to reorient itself and bind to the enzyme 
despite the presence of NNRTI resistance mutations.18
Pharmacology
Pharmacokinetics
Early phase I/II studies were conducted with a polyeth-
ylene glycol (PEG) capsule formulation (PEG4000) with 
low bioavailability and high pill burden, needing 900 mg 
twice a day to provide reliable pharmacokinetic profile.19 
The PEG formulation resulted in a high incidence of 
gastrointestinal side effects.20 A dose-finding, phase II, 
randomized clinical trial (TMC125-C223) comparing 
2 doses of the TF035 formulation (granular layered) of 
etravirine at 400 or 800 mg twice a day in addition to 2 or 
more approved antiretroviral agents selected the 800 mg 
twice a day for further development.21 A solid dispersion 
formulation using spray-drying technology was developed 
to improve etravirine bioavailability and reduce pill burden. 
A multiple-dose bioavailability study in HIV-infected indi-
viduals demonstrated similar steady-state pharmacokinetic 
exposure for the solid dispersion formulation at a dose of 
200 mg twice a day compared with the 800 mg twice a day 
of the granular-layered formulation with reduced interpa-
tient variability.22
Etravirine is currently formulated as a 100-mg tablet 
that has a more reliable pharmacokinetic profile without 
the frequent gastrointestinal side effects associated with the 
PEG capsule formulation. The dose approved by the FDA 
is 200 mg twice a day. When etravirine is administered 
under fasting conditions, the systemic exposure is decreased 
by 50%; therefore, etravirine should be administered after 
meals.23 In patients who have trouble swallowing tablets, the 
100-mg tablet can be dispersed in water with comparable 
bioavailability to the swallowed tablet.23,24
Population pharmacokinetic analysis of pooled data from 
DUET-1 and DUET-2 among 574 patients revealed an etra-
virine mean (SD) AUC12h and Cmin of 5,501 (4,544) ng⋅h/mL 
and 393 (378) ng/mL, respectively.25 In addition, the pooled 
analysis revealed a mean (SD) Cmax of 797 (668) ng/mL at 
week 24. Clearance (CL/F) was estimated to be 43.7 L/h, 
and the intersubject variability on CL/F was 60% with a 
40% intrasubject variability on fraction absorbed.25,26 It is 
important to mention that patients in both DUET trials were 
also treated with darunavir 600 mg/ritonavir 100 mg/twice 
a day, drugs that interact with etravirine.
Etravirine is 99.6% protein bound, primarily to albumin.13 
Maximal plasma concentration Tmax is reached in 2.5–4 hours, 
with an elimination half-life of 30–40 hours, which sug-
gests that once-a-day administration is a feasible option.19,26 
A multiple-dose pharmacokinetic study comparing etravirine 
monotherapy 200 mg twice a day with 400 mg once a day 
in healthy HIV-negative individuals was conducted. The 
systemic exposure was similar with a mean (SD) AUC12 
of 8,195 (2,428) ng/h/mL and mean (SD) AUC24 of 17,220 
(5,009) ng/h/mL for the twice-a-day vs once-a-day dose, 
respectively.26 The Cmin of etravirine was approximately 27% HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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lower for the once-a-day dose, and the Cmax of etravirine was 
approximately 45% higher for the once-a-day dose.26
The pharmacokinetics of etravirine is unchanged in 
patients with mild to moderate hepatic impairment. Etra-
virine has reduced CL/F in patients with hepatitis B or C 
coinfection; however, no dose adjustment is necessary.27 
The pharmacokinetics of etravirine has not been studied in 
patients with renal impairment.13
Pharmacodynamics
The DUET-1 and DUET-2 multisite, double-blind, ran-
domized, placebo-controlled phase III trials demonstrated 
superior virologic response when etravirine was compared 
with placebo, and when added to a combination regimen that 
included ritonavir-boosted darunavir.28–30 Factors predicting 
virologic response, defined as the proportion of patients with 
viral loads less than 50 copies/mL at 48 weeks, included 
lower baseline viral load, higher baseline CD4 cell count, 
better adherence, number of active agents in the background 
regimen, and baseline fold change (FC) in EC50 to etravirine.30 
Pharmacokinetic parameters of AUC12 and Cmin did not 
predict virologic suppression at week 48.30 Other factors, 
such as age, sex, race, and HIV clade, were not predictive 
of virologic response to etravirine at 48 weeks.30
Metabolism
Etravirine is a substrate of the hepatic cytochrome P450, 
and primarily metabolized by CYP3A4, CYP2C9, and 
CYP2C19, with its metabolites undergoing glucuronida-
tion. Etravirine is an inducer of CYP3A4 and an inhibitor 
of CYP2C9, CYP2C19, and P-glycoprotein; therefore, 
coadministration of drugs that are substrates of CYP3A4, 
CYP2C9, and CYP2C19 or are transported by P-glycoprotein 
may alter the therapeutic effect or adverse reaction profile of 
the coadministered drug.13,26 Etravirine concentrations may 
also be affected by drugs that alter CYP3A4, CYP2C9, or 
CYP2C19 activity and are expected to be higher in patients 
with reduced CYP2C9 or CYP219 activity.
Drug interactions
Since etravirine has mixed effects on the isoenzymes of 
the cytochrome P450, the potential drug interactions with 
NNRTIs, PIs, azoles antifungals, clarithromycin, rifamycins 
and other drugs, are extensive (Table 1). Etravirine should 
not be coadministered with unboosted PIs or with ritonavir-
boosted tipranavir. Coadministration with ritonavir-boosted 
fosamprenavir results in high exposure to fosamprenavir with 
potential toxicity; therefore, coadministration is discouraged. 
Coadministration with atazanavir 300 mg/ritonavir 100 mg 
results in a decrease in the atazanavir Cmin by 38%; therefore, 
the authors suggest increasing the atazanavir dose to 400 mg 
with 100 mg of ritonavir.13,26 Coadministration of etravirine 
and the new integrase inhibitors (raltegravir and elvitegravir) 
has been evaluated in healthy volunteers. When raltegravir 
and etravirine were used at the recommended doses of 400 
and 200 mg twice a day, respectively, there was a slight 
increase in etravirine exposure and a small decrease in the 
raltegravir exposure that were not clinically significant.31 
Similarly, no clinically relevant interaction was observed 
when elvitegravir and ritonavir at the dose of 150 and 100 mg 
once a day, respectively, were coadministered with etravirine 
200 mg twice a day.32
Coadministration of etravirine with CYP450 inducers, 
such as the anticonvulsants phenobarbital, phenytoin, and 
carbamazepine, as well as coadministration with the rifamy-
cins, rifampin or rifapentine, is contraindicated. However, 
rifabutin, a substrate and an inducer of CYP3A4, can be used 
in conjunction with etravirine without clinically significant 
interaction.13
Fluconazole and voriconazole are inhibitors of CYP3A, 
CYP2C9, and CYP2C19, and coadministration with etra-
virine resulted in a slight increase in etravirine steady-state 
exposure. The voriconazole and fluconazole exposures 
were virtually unchanged; therefore, dose adjustment is not 
necessary.26,33 Itraconazole and ketoconazole are substrates 
and potent inhibitors of CYP3A4 and could increase the 
etravirine exposure. In addition, etravirine could decrease 
the exposure of ketoconazole and itraconazole; therefore, 
caution should be exercised when etravirine is coadminis-
tered with these antifungals.34 Clarithromycin is an inhibi-
tor of CYP3A4 and when coadministered with etravirine, 
caused a 40% increase in etravirine exposure. The overall 
exposure of clarithromycin was reduced by 59%, while 
the 14-hydroxy-clarithromycin exposure was increased. 
Since the 14-hydroxy-clarithromycin has decreased activ-
ity against Mycobacterium avium complex, it is recom-
mended to consider azithromycin as an alternative treatment 
for M. avium complex infection.26 For a comprehensive 
review of the etravirine interactions with different medi-
cations, the reader is referred to the etravirine prescribing 
information.13
Efficacy studies
A double-blind, phase IIa clinical trial among HIV-infected, 
treatment-naive subjects randomized 2:1 to receive either 
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matched placebo as monotherapy was conducted as a proof 
of concept.19 After 7 days, patients treated with etravirine 
(n = 12) had a mean decrease in plasma HIV RNA of 
1.99 log10 copies/mL compared with 0.06 log10 copies/mL 
in the placebo arm (n = 7; P , 0.001).19
In an open-label, phase IIa trial, 16 individuals   receiving 
either efavirenz or nevirapine on virologic failure, defined 
as having HIV RNA viral load .2000 copies/mL and docu-
mented high-level phenotypic NNRTI resistance, substituted 
their failing NNRTI for etravirine 900 mg twice a day for 
7 days. After 7 days of treatment, a median 0.89 log10 copies/
mL decline in HIV RNA load was observed and 7 individuals 
(44%) had greater than 1 log10 decline in HIV RNA load.20
TMC125-C223 was an open-label, partially blinded, 
phase II randomized clinical trial, which evaluated the effi-
cacy of 2 doses of the TF035 (granular layered) formulation 
of etravirine at 400 or 800 mg twice a day in addition to 
2 or more approved antiretroviral agents, such as   nucleoside 
reverse transcriptase inhibitors (NRTIs) and lopinavir/
ritonavir and/or enfuvirtide. The comparator arm was an 
optimized regimen consisting of 3 or more FDA-approved 
drugs from 2 or more classes.21 The 199 patients studied 
were randomized 2:2:1 to etravirine 400 mg, 800 mg, and 
control, and had evidence of genotypic resistance to first-
generation NNRTIs and at least 3 primary PI mutations. 
The mean reduction in HIV RNA from baseline at week 
24 was 1.04, 1.18, and 0.19 log10 copies/mL for etravirine 
400 mg twice a day, 800 mg twice a day, and the control 
group, respectively (P , 0.05 for both etravirine groups 
compared with control).21 There was no significant differ-
ence in efficacy between the 2 etravirine doses; however, in 
patients not treated with enfuvirtide, or in patients treated 
Table 1 Significant etravirine drug interactions13,26,34,47
Drug Effect on ETR Effect on drug Comment
Protease inhibitorsa
Saquinavir/ritonavir  
1000/100 mg twice a day
33% ↓ AUC, 29% ↓ Cmin 20% ↓ Cmin No dose adjustment
Atazanavir/ritonavir 
300/100 mg every day
30% ↑ in Cmax,  
AUC and Cmin
38% ↓ in Cmin, 
14% ↓ in AUC
↑ ATV doseb
Fosamprenavir/ritonavir  
700/100 mg twice a day
No effect ↑ 62%–77% Cmax,  
AUC and Cmin
Avoid use
Lopinavir/ritonavirc 
400/100 mg twice a day
35% ↓ AUC, 45% ↓ Cmin 13% ↓ AUC, 20% ↓ Cmin No dose adjustment
Tipranavir/ritonavir  
500/200 mg twice a day
76% ↓ AUC, 82% ↓ Cmin 24% ↑ Cmin Avoid use
Darunavir/ritonavir  
600/100 mg twice a day
37% ↓ AUC, 49% ↓ Cmin 15% ↑ AUC No dose adjustment
Reverse transcriptase inhibitors
Didanosine 400 mg every day No effect No effect No dose adjustment
Tenofovir DF 300 mg every day 19% ↓ AUC, 18% ↓ Cmin 19% ↑ Cmin No dose adjustment
Integrase inhibitor
Raltegravir 400 mg twice a day 17% ↑ Cmin 34% ↓ Cmin No dose adjustment
elvitegravir/ritonavir 
150/100 mg every day
No effect No effect No dose adjustment
CCR5 antagonists
Maraviroc 300 mg twice a day  No effect 53% ↓ AUC, 39% ↓ Cmin ↑ Maraviroc to 600 mg twice a dayd
Other drugs
Rifabutin 300 mg every day 35% ↓ Cmin, 37% ↓ AUC 24% ↓ Cmin No dose adjustment
Clarithromycin 500 mg twice a day 42% ↑ AUC, 46% ↑ Cmin 39% ↓ AUC, 53% ↓ Cmin Avoid usee
Omeprazole 40 mg every day 41% ↑ AUC Not available No dose adjustment
Ranitidine 150 mg twice a day 14% ↓ AUC Not available No dose adjustment
Atorvastin 40 mg every day No effect 37% ↓ AUC No dose adjustment
Paroxetine 20 mg every day No effect No effect No dose adjustment
Methadone 60–130 mg/day No effect No effect Monitor for withdrawal
Sildenafil 50 mg single dose No effect 57% ↓ AUC Sildenafil dose needs to be ↑
aUnboosted protease inhibitors should not be used with etravirine; bTo 400 mg with 100 mg of ritonavir every day; cTablet; dIn the absence of boosted protease inhibitor. 
If ritonavir-boosted darunavir is combined with etravirine and maraviroc, the maraviroc dose should be 150 mg twice a day; eConsider using azithromycin; fMethadone 
maintenance dose may need to be adjusted.
Abbreviations: AUC, area under the plasma concentration-time curve; Cmin and Cmax, minimum and maximum plasma concentrations; ATV, atazanavir; eTR, etravirine;   
DF, disoproxil fumarate.HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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with only 1 active agent (other than   etravirine), the 800-mg 
dosage had greater virologic success.21   TMC125-C227 was 
a phase II, randomized, controlled, open-label 48-week trial 
comparing the efficacy of etravirine with an investigator-
selected PI in NNTRI-resistant, PI-naive HIV-infected 
patients. Patients were randomized to etravirine 800 mg 
twice a day (n = 59) or the control PI (n = 57), plus 2 
NRTIs.35 This trial was prematurely stopped when an 
unplanned interim analysis revealed suboptimal virologic 
response in individuals receiving etravirine in comparison 
with the control PI arm. The suboptimal virologic response 
in the etravirine arm was attributed to the high level of 
baseline NRTI and NNRTI resistance that made this arm 
virologicaly inferior to the PI-based control regimen. 
Therefore, the use of etravirine plus NRTIs alone will be 
suboptimal in PI-naive patients with first-line virologic 
failure on an NNRTI-based regimen.35
The DUET-1 and DUET-2 are multinational, random-
ized, double-blind, placebo-controlled phase III trials with 
identical design and conducted in different areas of the 
world. Treatment-experienced adults with virologic fail-
ure on stable antiretroviral therapy, documented NNRTI 
genotypic resistance, viral load over 5000 copies/mL, and 
3 or more primary PI mutations were randomly assigned 
to receive 200 mg of etravirine or placebo twice a day. All 
patients also received 600 mg of darunavir with 100 mg 
of ritonavir twice a day and investigator-selected NRTI. 
Enfuvirtide was optional. The primary intent-to-treat end 
point was a confirmed HIV RNA viral load of less than 
50 copies/mL at week 24 using the US FDA time-to-
loss of virologic response algorithm.28,29 At week 24, in 
DUET-1, 170 (56%) patients in the etravirine group and 
119 (39%) patients in the placebo group achieved a HIV 
RNA load of ,50 copies/mL (P = 0.005). HIV RNA viral 
load ,400 copies/mL was observed in 224 (74%) patients 
in the etravirine group and in 158 (51%) patients in the 
placebo group at week 24 (P = 0.0001). The mean decline 
in viral load from baseline in the etravirine group was 
2.41 log10 copies/mL compared with 1.70 log10 copies/mL 
in the placebo group (P , 0.0001). In addition, a greater 
increase in mean CD4 cell count was observed in the 
etravirine group compared with the placebo group at 
89 vs 64 cells/µL, respectively (P = 0.0002).28 In the DUET-
2, by week 24, 183 (62%) patients in the etravirine group 
and 129 (44%) patients in the placebo group achieved a HIV 
RNA load of ,50 copies/mL (P = 0.0003). HIV RNA viral 
load ,400 copies/mL was observed in 221 (75%) patients in 
the etravirine group and in 159 (54%) patients in the placebo 
group at week 24 (P = 0.0001). The mean decline in viral 
load from baseline in the   etravirine group was 2.34 log10 
copies/mL compared with 1.68 log10 copies/mL in the pla-
cebo group (P , 0.0001). The mean change in CD4 cell 
count from baseline was 78 vs 66 cells/µL for the etravirine 
and placebo groups, respectively (P = 0.36).29
Pooled 48-week analysis of the DUET studies showed 
durable virologic efficacy, with significantly more patients 
in the etravirine arm than in the placebo arm achieving 
viral load ,50 copies/mL (61% vs 40%, respectively; 
P , 0.0001).30 Patients taking etravirine achieved viro-
logic response significantly more quickly than patients 
taking placebo (median 15.7 and 32.7 weeks for etra-
virine and placebo, respectively; P , 0.0001). The mean 
48-week decline in viral load from baseline in the etra-
virine group was 2.25 log10 copies/mL compared with 
1.49 log10 copies/mL in the placebo group (P , 0.0001).30 
The mean increase in CD4 cell count was significantly 
higher in the etravirine group compared with the placebo 
group (98.2 vs 72.9 cells/µL, respectively; P = 0.0006). 
In addition, there were fewer AIDS-defining events or 
death in the etravirine group compared with the placebo 
group, with 35 (6%) vs 59 (10%) events, respectively 
(P = 0.04).30 Factors found to predict virologic response 
at 48 weeks were lower baseline viral load, higher CD4 
cell count, greater adherence, number of active agents in 
the background regimen, and less than 3 baseline FC in 
EC50 to etravirine.
Recently, a phase II, multicenter ANRS 139 TRIO trial 
evaluated the virologic response to a combination of 3 novel 
agents among patients on virologic failure with NRTI-, 
NNRTI-, and PI-resistant HIV . A total of 103 patients were 
enrolled and treated with raltegravir, darunavir, ritonavir, and 
etravirine at FDA-approved doses.36 The novel combination 
was well tolerated, with only 1 patient discontinuing treat-
ment due to adverse events. At week 48, 86% of patients had 
a HIV RNA viral load of ,50 copies/mL and a median CD4 
cell count increase of 108 cells/µL.36
Safety and tolerability
The 48-week pooled analysis on all 1,203 patients enrolled 
in DUET-1 and DUET-2 revealed no safety concerns, with 
the majority of adverse events being grade 1 or 2 in severity. 
The incidence of grade 3 or 4 adverse events was comparable 
between the etravirine and the placebo groups, and the mortal-
ity in the etravirine group was considered not related to study 
drug (Table 2).30 Rash was the only adverse event to occur sig-
nificantly more frequently in the etravirine group compared HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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with the placebo recipients (19.2% vs 10.9%; P = 0.0001). 
Within the etravirine group, grade 1 or 2 rash occurred in 
17.9% and grade 3 in 1.3%, with no grade 4 reported among 
patients exposed to etravirine. Rash occurred mainly during 
the second week of therapy with a median time to onset of 
14 days (range: 1–472 days). It generally resolved within 2 
weeks on continued therapy with a median duration of 15 
days (range: 1–402 days). Treatment discontinuation due to 
etravirine-associated rash occurred in 2.2% of patients.30 The 
incidence of etravirine-associated rash was higher in women 
than in men (30% vs 18%; P = 0.03). Patients with a history 
of NNRTI-related rash did not appear to have a higher risk 
for developing etravirine-related rash compared with patients 
with no history of NNRTI-related rash (22% vs 19%, respec-
tively). There was no association between baseline CD4 cell 
count and etravirine-associated rash regardless of sex. The 
  overall incidence of   neuropsychiatric disorders was low, and 
  disorders were mostly grade 1 or 2 events and comparable 
between the etravirine and placebo groups. The incidence of 
hepatic adverse events and laboratory abnormalities, includ-
ing hepatic and lipid parameters, were mostly grade 1 or 2 
in severity and comparable between the etravirine and the 
placebo groups (Table 2).30
Etravirine resistance
Etravirine-resistance-associated mutations (RAM) have 
been characterized both in vitro and in vivo.14,37 Unlike 
the first-generation NNRTIs, etravirine requires multiple 
mutations for the development of resistance (Table 3).37 
The impact of baseline genotype on virologic response to 
etravirine among subjects failing first-generation NNRTI 
was investigated in the DUET-1 and DUET-2 trials.28,29 Of 
the 44 NNRTI RAM, 13 mutations were initially identified 
by their association, with at least a 25% decline in response 
to etravirine compared with a subgroup of patients with 
no detectable NNRTI RAM at baseline.38 Recently, fur-
ther analysis of the pooled DUET-1 and DUET-2 data has 
expanded the number of etravirine RAM to 17, with Y181C 
and G190A being the most prevalent at baseline and present 
in 32% and 23.3% of patients, respectively, enrolled in the 
DUET studies (Table 3).39 The genotypic and phenotypic 
correlates of virologic response to etravirine defined as a 
HIV RNA load ,50 copies/mL at 24 weeks were examined 
by the pooled analysis of the DUET-1 and DUET-2 trials. 
A weighted genotypic score was developed by assigning a 
relative weight factor to each etravirine RAM according to 
its impact on virologic response and FC in the EC50. The 
relative weight factors were determined with random forest 
and linear modeling techniques, using matching genotypic 
and phenotypic data with virologic outcomes from the 
DUET trials and from a panel of NNRTI-resistant, recom-
binant HIV-1 clinical isolates.37 Among the 17 etravirine 
RAMs, the highest weight factor was assigned to Y181I and 
Y181V , with a weight factor of 3, followed by K101P, L100I, 
Y181C, and M230L, with a weight factor of 2.5 (Table 3). 
Etravirine-weighted genotypic score was graded as highest 
virologic response associated with the lowest score of 0–2, 
intermediate virologic response of 2.5–3.5, and reduced 
virologic response of $4, and correlated with virologic sup-
pression at 24 weeks in 74.4%, 52% and 37.7% of patients, 
respectively (Table 4).37 The effect of baseline etravirine FC 
Table 2 Adverse events reported in the DUeT-1 and DUeT-2 
studies at week 4830
Adverse event ETV + OBT  
(N = 599)
Placebo + OBT   
(N = 604)
Any adverse event, n (%) 575 (96) 580 (96)
Grade 3 or 4 adverse event 199 (33) 211 (35)
Serious adverse events 118 (20) 141 (23)
Rash (any type) 115 (19) 66 (11)
Diarrhea 118 (18) 142 (24)
Nervous system 103 (17) 119 (20)
Psychiatric 100 (17) 118 (20)
Nausea 89 (15) 77 (13)
Headache 65 (11) 77 (13)
Hepatic 39 (7) 37 (6)
Adverse events leading to
  Discontinuation 43 (7) 34 (6)
  Deaths 12 (2) 20 (3)
Selected grade 2–4 laboratory abnormalities
Triglycerides
  Grade 2 (500–700 mg/dL) 54 (9) 43 (7)
  Grade 3 (751–1200 mg/dL) 34 (6) 24 (4)
  Grade 4 (.1200 mg/dL) 21 (4) 11 (2)
Pancreatic amylase
  Grade 2 (.1.5–2 × ULN) 40 (7) 46 (8)
  Grade 3 (.2–5 × ULN) 44 (7) 51 (8)
  Grade 4 (.5 × ULN) 9 (2) 6 (1)
Total cholesterol
  Grade 2 (240–300 mg/dL) 117 (20) 101 (17)
  Grade 3 (.300 mg/dL) 48 (8) 32 (5)
LDL cholesterol
  Grade 2 (160–190 mg/dL) 76 (13) 69 (12)
  Grade 3 (.190 mg/dL) 42 (7) 39 (7)
Alanine aminotransferase
  Grade 2 (2.6–5 × ULN) 37 (6) 33 (6)
  Grade 3 (5.1–10 × ULN) 16 (3) 10 (2)
  Grade 4 (.10 × ULN) 6 (1) 2 (,1)
Aspartate aminotransferase
  Grade 2 (2.6–5 × ULN) 37 (6) 49 (8)
  Grade 3 (5.1–10 × ULN) 16 (3) 10 (2)
  Grade 4 (.10 × ULN) 3 (,1) 2 (,1)
Abbreviations: eTV, etravirine; OBT, optimized background therapy.HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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in EC50 on virologic suppression at week 24 was evaluated 
by analysis of covariance to determine the clinical cut-off 
values. The EC50 was derived from the Virco phenotype assay 
(Antivirogram®; Virco BVBA, Mechelen, Belgium). Patients 
with a baseline etravirine FC in EC50 of 3 or less had the 
highest virologic response (70.6%) (Table 4).37 Patients with 
intermediate response (50% virologic suppression) had an 
etravirine EC50 FC of .3 to #13, and patients with an etra-
virine EC50 FC of .13 had reduced response, with virologic 
suppression in only 36.7% of patients (Table 4).37
An alternate analysis of biological and clinical cut-off 
values was performed by Coakley et al on 199 baseline 
samples using the PhenoSense™ HIV (Monogram Biosci-
ences, San Francisco, California, USA).40 The lower clinical 
cut-off value for etravirine was defined as the FC above which 
HIV RNA response was first observed to decline relative to 
the reference population. Virologic outcomes were evaluated 
on the DUET studies at weeks 2, 4, 8, and 24 in relation to 
baseline etravirine FC. The biological cut-off was defined 
as the ninety-ninth percentile of etravirine FC values from 
1,693 viral isolates without mutations conferring resistance 
to NRTIs, NNRTIS, or PIs.40 In a model adjusted for the 
activity of the   background therapy, the activity of etravirine 
was observed to be reduced at a FC . 2.9. Further studies 
from the same group, using the lower clinical cut-off value 
of 2.9 FC to define reduced susceptibility, correlated a novel 
etravirine RAM weighting score with the relative impact on 
etravirine susceptibility in which a score of 4 or more defined 
reduced susceptibility.41 Mutations with a score of 4 were 
L100I, K101P, and Y181C/I/V . A score of 3 was assigned to 
E138A/G, V179E, G190Q, M230L, and K238N. A score of 
2 was assigned to K101E, V106A/I, E138K, V179L, Y188L, 
and G190S. A score of 1 was assigned to V90I, K101H, 
V106M, E138Q, V179D/F/M, Y181F, V189I, G190E/T, 
H221Y, P225H, and K238T.41,42 Contrary to the first-gen-
eration NNRTIs, the etravirine resistance patterns are more 
complex and continue to evolve. Recently, the combination of 
Y181C with N348I and 399D mutations, not included among 
Table 4 Relationship between genotypic and phenotypic susceptibility categories using the etravirine-weighted genotypic score37
Patients, n (%) Baseline etravirine fold change in EC50, n (%)
#3 (S) .3 to #13 (I) .13 (R)
etravirine-weighted genotypic score
0–2 (S) 225 (55.8) 208 (92.4) 16 (7.1) 1 (0.4)
2.5–3.5 (I) 101 (25.1) 42 (41.6) 31 (30.7) 28 (27.7)
.4 (R) 77 (19.1) 19 (24.7) 27 (35.1) 31 (40.3)
Abbreviations: eC50, 50% effective concentration; S, susceptible; I, intermediate; R, resistant.
Table 3 Genotype weight factor and FC in eC50 of etravirine-resistance-associated mutations37
Etravirine RAM Genotype weight factor Etravirine FC in EC50  
in HIV-1 clinical isolates
Etravirine FC in EC50
in a single SDM
Median n
Y181I 3.0 42.0 34 12.5
Y181V 3.0 10.4 28 17.4
K101P 2.5 22.3 65 6.2
L100I 2.5 6.7 264 1.8
Y181C 2.5 4.4 552 3.9
M230L 2.5 4.3 20 3.4
e138A 1.5 2.9 44 2.0
V106I 1.5 2.6 63 NA
G190S 1.5 0.8 32 0.2
V179Fa 1.5 NA 0 0.1
V90I 1.0 2.0 97 1.5
V179D 1.0 1.7 33 2.6
K101e 1.0 1.5 24 1.7
K101H 1.0 1.1 8 1.3
A98G 1.0 1.0 127 2.5
V179T 1.0 0.9 2 0.8
G190A 1.0 0.8 226 0.8
aV179F when present was always associated with Y181C.
Abbreviations: eC50, 50% effective concentration; RAM, resistance-associated mutations; FC, fold change; SDM, site directed mutant.HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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the etravirine RAM, caused a 6.4- to 12.6-fold reduction in 
etravirine susceptibility.43,44
Patient perspective and conclusion
Etravirine,  a  second-generation  NNRTI,  received 
FDA approval in January 2008 for the management of 
  treatment-experienced, HIV-infected adults with NNRTI-
resistant viruses. It has a high genetic barrier to resistance 
and is active against nevirapine- and efavirenz-resistant 
viruses. Etravirine is safe and well tolerated, it does not have 
the neuropsychiatric or hepatic side effects of efavirenz or 
nevirapine, and its safety profile is comparable to placebo 
with the exception of rash. Rash was grade 1 or 2 in the 
great majority of patients and was self-limited. History of 
NNRTI-related rash was not a predisposing factor. Etravirine 
is a pregnancy category B drug; its safety, pharmacokinetic 
profile, and efficacy have not been studied in pregnant 
women. Pediatric phase I/II studies are being conducted, and 
preliminary data suggest that it is safe and well tolerated. 
Pharmacokinetic studies in children between 6 and 17 years 
have shown that a dose of 5.2 mg/kg twice a day leads to 
exposure comparable to exposure by the adult dose of 200 
mg twice a day.45 In the DUET-1 and DUET-2 phase III 
efficacy trials, etravirine was always used in combination 
with ritonavir-boosted darunavir, a PI with antiviral activ-
ity in PI treatment-experienced patients. With the recent 
FDA approval of darunavir, raltegravir, and etravirine (and 
maraviroc for CCR5 tropic viruses), all with antiviral activity 
against multiple-drug-resistant HIV isolates, it is now pos-
sible for treatment-experienced patients to aim for virologic 
suppression comparable to treatment-naive patients as has 
been shown in the TRIO trial.36 In this trial, 86% of patients 
with multiple-drug-resistant HIV treated with raltegravir-, 
etravirine-, and ritonavir-boosted darunavir had a HIV RNA 
load of ,50 copies/mL at 48 weeks.36
In addition to the virologic efficacy, analysis from the 
DUET trials has shown a significant reduction in the hospital-
ization rate and in the number of hospitalization days among 
patients enrolled in the etravirine arm compared with the pla-
cebo arm.46 Ongoing studies on the pharmacokinetic interaction 
with newer agents; the safety, tolerability, and pharmacokinetic 
studies in children; and the prospect of once-a-day regimen due 
to the long half-life are subject to investigation.
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